# CheckMate 648 (NCT03143153)

> A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03143153
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Various Advanced Cancer
- Interventions: Nivolumab; Ipilimumab; Cisplatin; Fluorouracil
- Enrollment: 970
- Primary outcome: Overall Survival (OS) in Participants With Tumor Cell PD-L1
- Primary outcome: Progression-free Survival (PFS) as Assessed by BICR in Participants With Tumor Cell PD-L1

## Commentary we found

- X threads: 23
- Podcasts: 14
- YouTube: 12

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=checkmate-648-nct03143153

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03143153", "email": "<work email>"}; the inbox owner confirms by the emailed link.